Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01818752 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 955
- Enrollment target
- 20
- Study locations
NCT01818752 is a Phase 3 study of Multiple Myeloma that has completed, run by Amgen. The registered enrollment target is 955 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT01818752, a Phase 3 study of Multiple Myeloma, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 955 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade® (bortezomib), melphalan and prednisone (VMP).
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Prednisone
- DRUG Carfilzomib
- DRUG Bortezomib
Study Locations (20)
California
- California Cancer Associates for Research & Excellence, Inc. (cCARE) - Fresno
- Marin Cancer Care - Greenbrae
- Sutter Gould Medical Foundation - Modesto
- Innovative Clinical Research Institute - Whittier
New South Wales
- Royal Prince Alfred Hospital - Camperdown
- St. Vincent's Hospital Sydney - Darlinghurst
- Central Coast Local Health District - North Gosford
- Calvary Mater Newcastle - Waratah
South Carolina
- Saint Francis Health System - Greenville
- Spartanburg Regional Healthcare System - Spartanburg
- Santee Hematology Oncology - Sumter
New York
- Maimonides Cancer Center - Brooklyn
- Weill Cornell Medical Center - New York
Other
- Centro de educacion medica c investigacioncs clinicas "Norberto Quimo' (CEMIC) - Buenos Aires
- Sanatorio Britanico S.A. - Santa Fe
Florida
- UF Health Shands Cancer Hospital - Gainesville
Illinois
- Evanston KelIogg Cancer Center - Evanston
Montana
- Billings Clinic Cancer Center - Billings
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 955 participants |
| Start Date | 2013-07-08 |
| Est. Completion | 2016-11-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01818752
The ClinicalTrials.gov registry entry for NCT01818752 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 955 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (75% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Melphalan is the first listed.
NCT01818752 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, New South Wales, South Carolina.
Frequently Asked Questions
What is clinical trial NCT01818752 about?
NCT01818752 is a clinical study titled "Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma". The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade® (bortezomib), melphalan and prednisone (VMP).
What is the current status of trial NCT01818752?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 955 participants. The study started on 2013-07-08. Estimated completion is 2016-11-04.
What conditions does trial NCT01818752 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01818752?
The interventions under investigation include: Melphalan (DRUG), Prednisone (DRUG), Carfilzomib (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01818752?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01818752 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Montana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.